Mifegest Kit: Dosing Protocol and Clinical Guidelines
The Mifegest kit (mifepristone 200 mg + misoprostol 800 mcg) should be administered as mifepristone 200 mg orally on Day 1, followed by misoprostol 800 mcg buccally 24-48 hours later for termination of intrauterine pregnancy up to 70 days (9 weeks + 6 days) gestation 1.
Recommended Dosing Protocol
Standard Regimen
- Day 1: Mifepristone 200 mg orally
- Day 2-3 (24-48 hours later): Misoprostol 800 mcg buccally 1
The 24-48 hour interval between medications is critical for efficacy. Research demonstrates that concurrent administration significantly reduces effectiveness (68.8% vs 84.3% success rate, p=0.007) and increases continuing pregnancy rates (13.4% vs 2.8%, p=0.004) 2. Do not administer both medications simultaneously despite the convenience factor.
Route of Administration
Buccal misoprostol (800 mcg) is the FDA-approved route 1. While vaginal administration shows similar efficacy, buccal route is associated with fewer adverse effects compared to sublingual administration 3. The 800 mcg dose is superior to 400 mcg—the lower dose shows higher rates of incomplete abortion and continuing pregnancy 3.
Indications
Approved indication: Medical termination of intrauterine pregnancy through 70 days gestation (calculated from first day of last menstrual period) 1.
Contraindications
The following are absolute contraindications 1:
- Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass
- Chronic adrenal failure
- Concurrent long-term corticosteroid therapy
- History of allergy to mifepristone, misoprostol, or other prostaglandins
- Hemorrhagic disorders or concurrent anticoagulant therapy
- Inherited porphyria
- Intrauterine device (IUD) in place (must be removed before treatment)
Critical Safety Considerations
Ectopic pregnancy must be excluded before treatment 1. This is non-negotiable—the regimen will not terminate an ectopic pregnancy and delays appropriate management. Confirm intrauterine pregnancy location via ultrasound or clinical assessment.
Follow-Up Requirements
Mandatory follow-up is required to confirm complete termination of pregnancy 1. This typically occurs 7-14 days after mifepristone administration.
Follow-Up Assessment Should Include:
- Clinical evaluation for ongoing pregnancy symptoms
- Pelvic examination if indicated
- Ultrasound confirmation of complete abortion (preferred method)
- Assessment for complications
Expected Timeline
- Most patients (>95%) will experience complete abortion within 24-48 hours of misoprostol administration 4
- Bleeding typically begins within 4 hours of misoprostol use (88-92% of patients) 5
- Complete expulsion usually occurs within 24 hours 6
Warning Signs Requiring Immediate Evaluation
Instruct patients to seek immediate medical attention for 1:
- Sustained fever (may indicate infection even without other symptoms)
- Severe abdominal pain
- Prolonged heavy bleeding (soaking through 2 or more thick full-size sanitary pads per hour for 2 consecutive hours)
- Syncope or lightheadedness
- Abdominal pain or general malaise persisting >24 hours after misoprostol
Atypical Infection Presentation
A critical pitfall: Serious bacterial infections and sepsis can present without fever, bacteremia, or significant pelvic examination findings 1. Maintain high clinical suspicion even with subtle symptoms. This is a rare but potentially fatal complication.
Common Adverse Effects
Expected side effects (>15% incidence) include 1:
- Nausea
- Weakness
- Fever/chills
- Vomiting
- Headache
- Diarrhea
- Dizziness
These are typically self-limited and do not require intervention unless severe.
Additional Clinical Considerations
Rhesus Immunization
Rh immunoglobulin prophylaxis is required for Rh-negative patients, following the same protocol as surgical abortion 1.
Drug Interactions
- CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) can lower mifepristone concentrations and reduce efficacy 1
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase mifepristone concentrations—use with caution 1
- Avoid concurrent use with drugs having narrow therapeutic margins that are CYP3A4 substrates 1
Efficacy Data
The mifepristone-misoprostol combination regimen demonstrates 96-97% complete abortion rates through 63 days gestation 5. Efficacy remains high (95-97%) even at 64-70 days gestation with appropriate dosing 7. This combination is significantly more effective than misoprostol alone, which shows only 57.8% success rates in early pregnancy failure 8.
REMS Program
Mifeprex is only available through a restricted program called the Mifepristone REMS Program 1. Prescribers must be certified, and patients must sign a Patient Agreement Form acknowledging risks and follow-up requirements.